Diabetes News Roundup: November 2018

Highlights include an online diabetes prevention program; sweetened drinks pose greater diabetes risk; and the link between night shifts and T2DM.

Related Videos

Related Content

Advertisement

December 6th 2024

A Pillared Approach: A Suite of Therapies for a Spectrum of Metabolic Disease

Patrick Campbell

November 21st 2024

Diabetes Dialogue: News and Updates in Diabetes at AHA 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE

December 4th 2024

Endoscopy in the Age of GLP-1 RAs: 2024 Sees New Risk-Based Perioperative Guidance

Abigail Brooks, MA

November 11th 2024

Diabetes Dialogue: Diabetes Tech Updates in October 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE

November 26th 2024

Obesity Drug MariTide Achieves Up to 20% Weight Loss in Phase 2 Trial

Connor Iapoce

November 18th 2024

More than 50% of US Adults Considered Eligible for Semaglutide with Current Labeling

Patrick Campbell

Related Content

Advertisement

December 6th 2024

A Pillared Approach: A Suite of Therapies for a Spectrum of Metabolic Disease

Patrick Campbell

November 21st 2024

Diabetes Dialogue: News and Updates in Diabetes at AHA 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE

December 4th 2024

Endoscopy in the Age of GLP-1 RAs: 2024 Sees New Risk-Based Perioperative Guidance

Abigail Brooks, MA

November 11th 2024

Diabetes Dialogue: Diabetes Tech Updates in October 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE

November 26th 2024

Obesity Drug MariTide Achieves Up to 20% Weight Loss in Phase 2 Trial

Connor Iapoce

November 18th 2024

More than 50% of US Adults Considered Eligible for Semaglutide with Current Labeling

Patrick Campbell